Sartorius stock stays supported by 2025 earnings

Sartorius stock is anchored by 2025 figures that show revenue of EUR 3.38 billion, EBITDA of EUR 929 million, and a 16.8% EBITDA margin. The company (ISIN DE0006292006) is the focus here because those published numbers remain the latest hard reference point in a thin market-information setting.

2025 revenue and margin

In fiscal 2025, Sartorius reported revenue of EUR 3.38 billion and EBITDA of EUR 929 million, according to the company context available in this call. The EBITDA margin stood at 16.8% for the year, which gives investors a clear operating benchmark for the group’s recent profitability profile.

The comparison embedded in those figures matters: EUR 929 million of EBITDA on EUR 3.38 billion of revenue implies a business that is still generating substantial cash earning power even after a weaker industrial backdrop. The 16.8% margin also frames how much room there is for further recovery if volumes improve.

What the numbers say

The latest structured evidence points to a company that is still sizable, still profitable, and still sensitive to margin execution. Revenue of EUR 3.38 billion in 2025 and EBITDA of EUR 929 million are not abstract profile data; they are the base from which the next update will be judged.

For investors, the key comparison is not a day-to-day price move but the relationship between sales and earnings. A 16.8% EBITDA margin is a useful way to track whether Sartorius can keep converting revenue into operating profit at a steady rate.

Product focus matters

Sartorius sells tools and consumables used in biopharmaceutical production, so product demand tends to show up first in recurring orders and margin quality. That business mix helps explain why revenue and EBITDA remain the most useful headline metrics for the share story.

When the company next reports fresh figures, investors will compare those new numbers against the 2025 base of EUR 3.38 billion in revenue and EUR 929 million in EBITDA, not against a generic corporate narrative. The margin line, at 16.8%, is the cleanest shorthand for that comparison.

Stock level and venue

Sartorius shares trade on Xetra in EUR, and the stock reference point for this article is the company’s published 2025 operating data rather than a live intraday quote. That keeps the focus on evidenced fundamentals: EUR 3.38 billion of revenue, EUR 929 million of EBITDA, and a 16.8% margin.

In that context, the stock is best read as a claim on future earnings recovery rather than on a single-day catalyst. The next hard update will matter most if it changes the relationship between sales growth and margin delivery.

Sartorius product and segment

The most relevant representative business line is Sartorius Bioprocess Solutions, which sits at the center of the group’s earnings mix and customer exposure. Its importance is visible in the way revenue and EBITDA are used to measure the broader company.

Sartorius stock closing view

Sartorius stock is assessed here through the latest published 2025 figures, not a live quote: revenue was EUR 3.38 billion, EBITDA was EUR 929 million, and the EBITDA margin was 16.8%. That combination leaves the market watching whether the next reporting cycle improves the conversion from sales to profit.